

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated 01-2-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 30-9-2006 TO BE PUBLISHED ON 02-1-2007IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1237/2006	<u>25-09-2006</u> Actimis Pharmaceutical, Inc. USA (Priority 25-4-03 Europe) Divisional	“ A tautomeric or stereoisomeric form, or a salt, ester, or prodrug of a pyrimidine derivative and a pharmaceutical composition thereof for the treatment of diseases mediated by crth2 ”
1238/2006	Otsuka Pharmaceutical co., Ltd. Japan (Priority 29-1-04 Japan) Divisional	“ A pharmaceutical composition containing piperidine compound for promoting angiogenesis ”
1239/2006	Novartis AG, Switzerland (Priority 28-9-05 GB)	“ Organic compounds”
1240/2006	Novartis AG, Switzerland (Priority 27-9-05 USA)	“ Carboxyamine compounds and methods of use thereof”
1241/2006	LG Life Sciences, Ltd. Korea (Priority 27-9-05 Korea)	“ hFSH aqueous formulations”
1242/2006	Wyeth, USA (Priority 26-9-2005 USA)	“Amino-5[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β -secretase”
1243/2006	Honeywell International, Inc. USA	“Prilling method”
1244/2006	<u>26-09-2006</u> Sumitomo Chemical Co. Ltd., Japan (Priority 14-10-2005 Japan)	“Hydrazide compound and pesticidal use of the same”
1245/2006	Honda Motor Co. Ltd., Japan (Priority 31-10-2005 Japan)	“Winker mounting structure”

1246/2006	Glaxo Group Limited, Great Britain (Priority 23-04-2003 GB)	“A pharmaceutically acceptable salt of a piperidine carbonyl derivative, process for its preparation and a pharmaceutical composition comprising thereof”
1247/2006	Merck Co., Inc., USA (Priority 05-10-2005 USA)	“Anti-hypercholesterolemic compounds”
1248/2006	Novartis AG, Switzerland (Priority 29-09-2005 USA)	“New formulation”
1249/2006	Wyeth, USA (Priority 21-02-2003 USA)	“Pharmaceutically acceptable salts of 4-[2, 4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury”
1250/2006	Wyeth, USA (Priority 15-10-2003 USA)	“Pharmaceutically acceptable salts for oral administration of [2-(8, 9-dioxo-2, 6-diazabicyclo[5. 2. 0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives”
1251/2006	1. Glaxo Group Limited, UK 2. Alcan Technology & Management Ltd., Switzerland (Priority 27-9-05 Europe)	“Lid sheet for use in a blister pack”
1252/2006	<u>27-09-2006</u> 1. Prof. dr. Muhammad Javed Iqbal, 2. Qaisar Mahmood Malik, Department of Chemistry Quaid-Azam, University Islamabad, Pakistan	“Development and validation of a new reverse phase HPLC method for determination of vitamin B12 in drug substance, tablets and syrup formulation”
1253/2006	Merck & Co., Inc. USA Divisional	“Pharmaceutically acceptable salt of indoles having anti-diabetic activity”

1254/2006	F. Hoffmann-La Roche AG, Switzerland (Priority 06-12-1999 USA) Divisional	“A pharmaceutically acceptable salt of 4-pyrimidinyl-N-Acyl-L-Phenylalanine”
1255/2006	F. Hoffmann-La Roche AG, Switzerland (Priority 06-12-1999 USA) Divisional	“4-Pyrimidinyl-N-Acyl-L-Phenylalanine”
1256/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 29-09-2005 EP)	“Derivatives of -2 Aminothiazoles and 2-Aminooxazoles, Processes for their preparation and their use as pharmaceuticals”
1257/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 29-09-2005 EP)	“Phenyl-1,2,4-Oxadiazolone derivatives, Processes for their preparation and their use as pharmaceuticals”
1258/2006	Novartis AG, Switzerland (Priority 30-09-2005 USA)	“Organic Compounds”
1259/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 29-09-2005 EP)	“Phenyl-1,2,4-Oxadiazole derivatives, processes for their preparation and their use as pharmaceuticals”
1260/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 29-09-2005 EP)	“Phenyl-[1,2,4]-Oxadiazol-5-One derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals”
1261/2006	Novartis AG, Switzerland (Priority 20-07-2002 UK) Divisional	“A polymorphic crystal form of 3-Methylthiophene 2- Carboxylic acid”
1262/2006	Novartis AG, Switzerland (Priority 30-09-2005 USA)	“Organic Compounds”

1263/2006	Glaxo Group Limited, UK (Priority 18-07-2003 GB) Divisional	“A quinoline and quinazoline compound having affinity for 5HT1- type receptors”
1264/2006	Wyeth USA (Priority 29-09-2005 USA)	“Substituted propylamine derivatives and methods of their use”
1265/2006	Wyeth U.S.A. (Priority 29-09-2005 USA)	“Phenylaminopropanol derivatives and methods of their use”
1266/2006	Syngenta Limited UK (Priority 27-09-2005 USA)	“Improved insecticidal Textile material”
1267/2006	Wyeth USA (Priority 29-09-2005 USA)	“Benzothiadiazolyphenylalkylamine derivatives and methods of their use”
1268/2006	Wyeth USA (Priority 27-09-2005 USA) <u>28-9-2006</u>	“Thieno[2,3-B]Pyridine-5-Carbonitriles as protein kinase Inhibitors”
1269/2006	AstraZeneca AB. Sweden (Priority 06-10-2005 USA)	“Therapeutic Agents”
1270/2006	Merck Frosst Canada & Co Canada (Priority 29-08-2001 USA) Divisional	“A Pharmaceutically acceptable salt of alkyne-aryl phosphodiesterase-4 inhibitor”
1271/2006	AstraZeneca AB Sweden (Priority 01-02-2002 EP) Divisional	“A salt of 7-benzyloxy-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline”
1272/2006	AstraZeneca AB Sweden (Priority 01-02-2002 EP) Divisional	“A Salt of 4-(4-fluoro-2-methylindol-5-yloxy)-7-hydroxy-6-methoxyquinazoline”

1273/2006	SmithKline Beecham Corporation USA (Priority 30-09-2005 US)	“Pharmaceutical Compositions”
1274/2006	1.SB Pharmco Puerto Rico Inc. Puerto Rico 2.Neurocrine BioSciences Inc. USA (Priority 30-09-2005 GB)	“Chemical Compound”
1275/2006	Glaxo Group Limited UK (Priority 30-09-2005 GB)	“Compounds which have activity at M1 Receptor and their uses in medicine”
1276/2006	Dystar Textilfarben GmbH & Co., Germany (Priority 01-10-2005 Germany)	“Dyes and dye mixtures for polymer coloration, their preparation and their use”
1277/2006	Glaxo Group Limited UK (Priority 30-09-2005 GB)	“Compounds which have activity at M1 Receptor and their uses in medicine”
1278/2006	Berlin-Chemie AG Germany (Priority 29-09-2005 Germany)	“Photostable Pharmaceutical composition containing brivudine for the treatment of herpetic keratitis”
1279/2006	N.V. Organon Netherlands (Priority 30-09-2005 EP)	“9-Azabicyclo[3.3.1] Nonane derivatives”
1280/2006	De La Rue International Ltd., UK (Priority 30-09-2005 GB)	“Security device for security substrates”
1281/2006	Wyeth, USA (Priority 29-10-03 USA) Divisional	Pharmaceutically acceptable salts of sustained release pharmaceutical compositions”
1282/2006	<u>29-9-2006</u> AstraZeneca AB, Sweden	“ New compounds”

(Priority 03-10-05 Sweden)

1283/2006	AstraZeneca AB, Sweden (Priority 03-10-05 Sweden)	“ New compounds”
1284/2006	AstraZeneca AB, Sweden (Priority 03-10-05 Sweden)	“ Chemical compounds”
1285/2006	Nokia Corporation, Finland (Priority 29-9-05 USA)	“Apparatus, method and computer program product to request a data rate increase based on ability to transmit at least one more selected data unit”.
1286/2006	Nokia Corporation, Finland (Priority 29-9-05 USA)	“Method, device, system and software product for providing system information to enable packet switched handover”
1287/2006	Wyeth, USA (Priority 14-10-2003 USA) Divisional	“ Composition for treating vasomotor symptoms”
1288/2006	1. Arena Pharmaceuticals, Inc. 2. Merck & Co., Inc. USA (Priority 31-10-03 USA) Divisional	“ A tetrazole derivative and pharmaceutical composition thereof for the treatment of metabolic-related disorders”
1289/2006	Glaxo Group Limited, United Kingdom (Priority 08-6-2001 GB) Divisional	“ A pharmaceutically acceptable solvate of a sulphonamide, derivative process for its preparation and a pharmaceutical composition comprising thereof for use as a factor Xa inhibitor”
1290/2006	F. Hoffmann-La Roche AG, Switzerland (Priority 19-7-01 Europe) Divisional	“ Novel salt of dolastatin 10 compound having improved anti-tumor properties”
1291/2006	F. Hoffmann-La Roche AG, Switzerland (Priority 19-7-01 Europe)	“ Novel dolastatin 10 compound having improved anti-tumor properties”

	Divisional	
1292/2006	Bristol-Myers Squibb Company, USA Divisional	“ Pharmaceutically acceptable salt of antidiabetic and antiobesity agent ”
1293/2006	30-9-2006 Orca V.O.F., Netherlands	“ Ship with liquid transport tanks provided with deformation absorbers”
1294/2006	Arthur Benjamin O’ Connor. Australia (Priority 04-10-05 Australia)	“ Wind Turbine”
1295/2006	Honda Motor Co., Ltd. Japan (Priority 30-11-05 Japan)	“ Internal combustion engine and motorcycle”
1296/2006	E.I. DU Pont DE Nemours and Co., USA (Priority 23-11-05 USA)	“ Amidinylphenyl compounds and their use as fungicides”
1297/2006	Bristol-Myers Squibb Co., USA (Priority 10-3-2000 USA) Divisional	“ Salt of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV”
1298/2006	AstraZeneca AB, Sweden (Priority 16-9-03 GB) Divisional	“ A pharmaceutically acceptable salt of quinazoline derivative”
1299/2006	Merck Sharp & Dhome Limited England (Priority 21-8-01 GB) Divisional	“ A pharmaceutically acceptable sodium salt of the compound cis-4[(4-chlorophenyl) sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoic acid”
1300/2006	Anor MED Inc, Canada (Priority 18-5-2000 GB) Divisional	“ A pharmaceutical composition which comprises a prodrug of the sterically hindered platinum coordination compound”

1301/2006	AstraZeneca AB, Sweden (Priority 24-10-03 GB) Divisional	“ A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R, 5S)-3,5-dihydroxyhept-6-enoic acid”
1302/2006	AstraZeneca AB, Sweden (Priority 31-05-02 Sweden) Divisional	“Modified release pharmaceutical composition”
1303/2006	AstraZeneca AB, Sweden (Priority 31-05-02 GB) Divisional	“Immediate release composition comprising certain mandelic and composition and its use in the treatment of conditions where inhibition of thrombin is required”
1304/2006	Novartis AG, Switzerland (Priority 30-09-2005 USA) Divisional	“2-amino-7, 8-dihydro-6H-pyrido[4, 3-D]pyrimidin-5-ones”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

104/2005 1. Mr. Muhammad Kamil "A process for recovery of silver nitrate from waste
2. Mr. Muhammad Ishaq indelible ink"
Qaimkhani,
P.C.S.I.R. Karachi.

(Class: C01G 5/00)

139221

Process for the recovery of silver nitrate from ink by soaking 3000 ink vials in 20 liter hot distilled H₂O & then in 1-liter Conc. HNO₃. After 24 hours dye is removed by filtering & by evaporation silver nitrate is obtained.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139078	Glaxo Group Limited, United Kingdom	666/2004
139079	1. Arif Karim 2. Muhammad Yaqub, 3. Kamran Hafeez and 4. Faisal Ghazanfar Karachi, Pakistan	669/2004
139080	Wyeth, USA	670/2004

139081	Honda Motor Co., Ltd., Japan	672/2004
139082	Chee Siang Industrial Co., Ltd., Republic of China	678/2004
139083	Ultra Motor Company Limited, UK	680/2004
139084	1. Wyeth, USA 2. Board of Regents, USA	682/2004
139085	Honda Motor Co. Ltd., Japan	684/2004
139086	Alizyme Therapeutics Limited, UK	687/2004
139087	Methanol Casale S.A., Switzerland	691/2004
139088	1. Warner-Lambert Company LLC., USA 2. Abgenix Inc., USA	695/2004
139089	AuVitronics Ltd., Karachi, Pakistan	960/2004
139090	Unilever Plc, England	968/2004
139091	Shell Internationale Research Maatschappij B.V., The Netherlands	991/2004
139092	Unilever Plc, England	992/2004

139093	Clariant International Ltd., Switzerland	996/2004
139094	Aventis Pharmaceuticals Inc., USA	998/2004
139095	Unilever Plc, England	1001/2004
139096	Bayer CropScience AG, Germany	1002/2004

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488